Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology · 2026
The effect of HBE1 on resistance to gemcitabine in pancreatic cancer cells.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cheng Jiyun, Jiang Haixing, Yu Xianen, Huang Peining, Lu Yihan, Tan Shudan, Liu Xiaojun, Qin Shanyu
Аннотация
BACKGROUND: Chemotherapy resistance remains a major challenge in pancreatic cancer treatment, with gemcitabine-based therapy being a primary approach. However, the mechanisms underlying gemcitabine resistance in pancreatic cancer cells are not yet fully understood. This study aimed to investigate the role ofHBE1in conferring resistance to gemcitabine and explore its effects on reactive oxygen species (ROS) production, mitochondrial apoptosis, and endoplasmic reticulum (ER) stress.
MATERIALS AND METHODS: A gemcitabine-resistant pancreatic cancer cell line was systematically developed through gradual, six-month exposure to increasing concentrations of gemcitabine. The role ofHBE1was examined by assessing its impact on ROS levels, mitochondrial-mediated apoptosis, and ER stress pathways, includingIRE1α phosphorylationandGRP78 expression.
RESULTS: Overexpression ofHBE1was found to suppress ROS generation and inhibit mitochondrial-dependent apoptosis. Additionally, it attenuated ER stress by reducingIRE1α phosphorylationwhile upregulatingGRP78.
CONCLUSION: These findings demonstrate a strong correlation between elevatedHBE1expression and gemcitabine resistance in pancreatic cancer cells, suggesting its potential as a therapeutic target to overcome chemoresistance.
MATERIALS AND METHODS: A gemcitabine-resistant pancreatic cancer cell line was systematically developed through gradual, six-month exposure to increasing concentrations of gemcitabine. The role ofHBE1was examined by assessing its impact on ROS levels, mitochondrial-mediated apoptosis, and ER stress pathways, includingIRE1α phosphorylationandGRP78 expression.
RESULTS: Overexpression ofHBE1was found to suppress ROS generation and inhibit mitochondrial-dependent apoptosis. Additionally, it attenuated ER stress by reducingIRE1α phosphorylationwhile upregulatingGRP78.
CONCLUSION: These findings demonstrate a strong correlation between elevatedHBE1expression and gemcitabine resistance in pancreatic cancer cells, suggesting its potential as a therapeutic target to overcome chemoresistance.